Genopole(R) and Three of its Campus Companies Will Attend the International BIO 2007 Trade Show

Evry, France (ots/PRNewswire) - The 2007 edition of the BIO
(Biotechnology Industry Organization) trade show will be held in
Boston (may 6-9). Genopole will attend this major event as part of a
delegation coordinated by the Paris Il-de-France Regional Development
Agency (ARD). Three innovative companies supported by Genopole(R) -
Genewave, MATBiopharma and Vaxon Biotech - will equally be present at
the show.

"The annual BIO show attracts the world's key biotech players. For
a biocluster like Genopole, it's an event that we can't afford to
miss", explains Pierre Tambourin, Genopole CEO. Since its foundation
in 1998, Genopole has attended this event on a regular basis -
enabling the cluster to achieve true international visibility."

"The BIO event enables us to meet our foreign counterparts and
benefit from their experience but also allows us to showcase the
novel approaches to biotech business support that we have implemented
here at Genopole", adds Pierre Tambourin. In fact, our biopark stands
out by combining a company incubator and a pre-seed fund (Genopole
Day One), backed up by scientific and industrial infrastructure.
Thanks to a broad array of financial, technological, scientific and
real estate tools, a dense, rich fabric of companies has formed
around Genopole."

Therapeutic innovation is the core concern of Genopole's
stakeholders. The forthcoming establishment of a University Medical
Center unit and the creation of a biomanufacturing facility at the
heart of the campus will add the final building blocks to a
biocluster which is already generating innovative medical techniques.

The Genopole portfolio now includes 62 enterprises, of which 35
have been founded or incubated on the campus. The Genopole biopark
(with a strong biopharmaceutical theme) brings together drug
discovery & development companies, technology providers and service
companies. Twenty business have already commercialized products
and/or services and 22 therapeutics are currently under development
for a range of indications.

Three Genopole-mentored companies - Genewave, MATBiopharma and
Vaxon Biotech (see over) - will attend the international BIO
convention this year. "This event will offer our companies a great
opportunity to showcase their products, skills and know-how. The
business conventions, seminars and forums provide a host of occasions
for meeting their future partners and customers", explains Véronique
Dufey, Executive Director of Genopole Enterprise.

Three companies from the Genopole(R) portfolio will attend BIO
2007

Genewave develops, manufactures and sells a range of innovative
biophotonic instruments and consumables for fl uorescence-based
genomics and proteomics analysis techniques. This includes high
sensitivity biochip substrates, compact biochip readers and systems
with integrated fluidics as well as components for lab-on-a-chip
devices. The Company also offers surface functionalization services.

Ongoing developments:

Ultrasensitive systems, multiwell microarray readers, integrated
microsystems, specifi c surface chemistries.

Contact: Claude Weisbuch, CEO claude.weisbuch@genewave.com;
www.genewave.com

About MATBiopharma

Immuno Targeting Company

MATBiopharma is engaged in the development of first-in-class
antibody therapies for the treatment of cancer. The Company's most
advanced product, Ferritarg(TM), is an antibody therapeutic for the
treatment of Hodgkin's disease and will soon enter Phase I/II
clinical trials. The MAT preclinical pipeline contains product
candidates for acute myeloid leukemia, chronic lymphocytic leukemia,
hepatocarcinoma, pancreatic cancer and metastatic melanoma. MAT is
currently seeking partners in the US in order to accelerate
downstream development of these compounds.

Contact : Frédéric Gomez, Head of Corporate and Business
Development f.gomez@matbiopharma.fr - www.matbiopharma.fr

About Vaxon Biotech

New Horizons in Cancer Vaccine Therapy

Vaxon Biotech (founded in early 2004) is a product-driven
biopharmaceutical company focusing on the discovery and development
of innovative vaccines for the treatment of cancer. Vaxon Biotech is
the first entrant to make vaccines with a new class of antigens:
optimized cryptic peptides. These innovative vaccines show good
tolerance and immunogenicity, both in animals and in Phase I cancer
patients. The most advanced products are Vx-001 and Vx-006. Treatment
with Vx-001 induced lengthy disease stabilization or a partial
response in about 30% of patients. Vx-001 is due to enter a pivotal
phase IIb clinical trial in hepatocellular cancer, together with a
phase IIa study in non-small cell lung cancer. Vx-006, the second
compound, should enter phase I/II clinical development in the
prostate cancer field by Q4-2006.

Contact : Philippe Berthon, CEO

pberthon@vaxon-biotech.com - www.vaxon-biotech.com

Press Contact :
Genopole Communication
Caroline Villedieu
+33-1-60-87-44-98
caroline.villedieu@genopole.fr
Contact Genopole Enterprise :
Executive Director of Genopole Enterprise
Véronique Dufey
veronique.dufey@genopole.fr
+33-1-60-87-84-46
www.genopole.fr

ots Originaltext: Genopole
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Press Contact : Genopole Communication, Caroline Villedieu,
+33-1-60-87-44-98, caroline.villedieu@genopole.fr; Contact Genopole
Enterprise : Executive Director of Genopole Enterprise, Véronique
Dufey, veronique.dufey@genopole.fr, +33-1-60-87-84-46